Research with the drug tofacitinib for patients with refractory celiac disease type II
Recruiting
- Conditions
- <p>Refractory Celiac Disease type IIRCDIIRefractaire Coeliakie type II</p>
- Registration Number
- NL-OMON25125
- Lead Sponsor
- Amsterdam UMC, location VU University Medical Center
- Brief Summary
A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 5
Inclusion Criteria
1. Adult patients ≥ 18 years old
2. Given informed consent
Exclusion Criteria
1. Diagnosis of RCDI, EATL
2. Presence of any of the following diagnosis:
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary efficacy endpoint: <br>- Immunological response, as defined by: <br>reduction of = 20% from baseline of aberrant IELs (%) with respect to total IELs in duodenal biopsies at week 12, as assessed by flow cytometry.</p>
- Secondary Outcome Measures
Name Time Method